Chromocell Therapeutics announced that its board of directors has authorized a stock repurchase plan of up to $250,000 of Chromocell’s common stock, which represents approximately 23% of the non-affiliate float based on the closing price of the Company’s Common Stock as of August 6, 2024. The Repurchase Plan does not obligate the Company to acquire any particular amount of Common Stock, and it may be modified, extended or terminated by the Board of Directors at any time.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRO:
- Chromocell Announces Stock Repurchase Plan
- Chromocell Therapeutics Strengthens Finances with Strategic Agreements
- Chromocell Therapeutics files to sell 2M shares of common stock for holders
- Chromocell to Participate in the Virtual Investor Lunch Break Series
- Apple downgraded, Kroger upgraded: Wall Street’s top analyst calls
Questions or Comments about the article? Write to editor@tipranks.com